biomedicines

IMPACT FACTOR 3.9

Indexed in: PubMed

CITESCORE 6.8

an Open Access Journal by MDPI

Targeting the Resistant Tumor Microenvironment in Lymphoma: From Basic Science to Artificial Intelligence

Guest Editor:

Dr. Rada Amin
Department of Biochemistry, University of Nebraska-Lincoln, Lincoln, NE, USA

Deadline for manuscript submissions:
closed (31 January 2025)

Message from the Guest Editor

Despite recent advances in lymphoma treatment, achieving a durable response remains poor, leading to relapse and resistance to various immunotherapies. Current challenges in reaching a complete response include the high degree of heterogeneity in the tumor microenvironment (TME) composition and the multitude mechanisms through which the TME can counteract the efficacy of therapy. The high pressure exerted by treatments results in the modulation of TME response prompting necessary signals for the development of resistant clones against therapeutic regimens.

Therefore, further research is necessary to explore the complex molecular and cellular ecosystem of lymphoma disease and reveal innovative microenvironmental targets that can reduce the high incidence of relapse and resistance and minimize the development of drug-resistant clones.

This Special Issue welcomes reviews and innovative research articles spanning from basic science to artificial intelligence approaches on the TME-lymphoma crosstalk. The aim is to enhance our understanding of the influence of TME on malignancies and improve therapy effectiveness.

biomedicines

IMPACT FACTOR 3.9 | Indexed in: PubMed | CITESCORE 6.8

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
𝕏@Biomed_MDPI